Literature DB >> 31796631

Biased M1 receptor-positive allosteric modulators reveal role of phospholipase D in M1-dependent rodent cortical plasticity.

Sean P Moran1,2,3, Zixiu Xiang2,3, Catherine A Doyle3, James Maksymetz2,3, Xiaohui Lv3, Sehr Faltin3, Nicole M Fisher2,3, Colleen M Niswender2,3,4, Jerri M Rook1,2,3, Craig W Lindsley2,3,5, P Jeffrey Conn6,2,3,4.   

Abstract

Highly selective, positive allosteric modulators (PAMs) of the M1 subtype of muscarinic acetylcholine receptor have emerged as an exciting new approach to potentially improve cognitive function in patients suffering from Alzheimer's disease and schizophrenia. Discovery programs have produced a structurally diverse range of M1 receptor PAMs with distinct pharmacological properties, including different extents of agonist activity and differences in signal bias. This includes biased M1 receptor PAMs that can potentiate coupling of the receptor to activation of phospholipase C (PLC) but not phospholipase D (PLD). However, little is known about the role of PLD in M1 receptor signaling in native systems, and it is not clear whether biased M1 PAMs display differences in modulating M1-mediated responses in native tissue. Using PLD inhibitors and PLD knockout mice, we showed that PLD was necessary for the induction of M1-dependent long-term depression (LTD) in the prefrontal cortex (PFC). Furthermore, biased M1 PAMs that did not couple to PLD not only failed to potentiate orthosteric agonist-induced LTD but also blocked M1-dependent LTD in the PFC. In contrast, biased and nonbiased M1 PAMs acted similarly in potentiating M1-dependent electrophysiological responses that were PLD independent. These findings demonstrate that PLD plays a critical role in the ability of M1 PAMs to modulate certain central nervous system (CNS) functions and that biased M1 PAMs function differently in brain regions implicated in cognition.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Year:  2019        PMID: 31796631      PMCID: PMC6936752          DOI: 10.1126/scisignal.aax2057

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  73 in total

Review 1.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Authors:  Terry P Kenakin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

Authors:  Rodrigo Medeiros; Masashi Kitazawa; Antonella Caccamo; David Baglietto-Vargas; Tatiana Estrada-Hernandez; David H Cribbs; Avraham Fisher; Frank M LaFerla
Journal:  Am J Pathol       Date:  2011-06-23       Impact factor: 4.307

3.  Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.

Authors:  A Ghoshal; J M Rook; J W Dickerson; G N Roop; R D Morrison; N Jalan-Sakrikar; A Lamsal; M J Noetzel; M S Poslusney; M R Wood; B J Melancon; S R Stauffer; Z Xiang; J S Daniels; C M Niswender; C K Jones; C W Lindsley; P J Conn
Journal:  Neuropsychopharmacology       Date:  2015-06-25       Impact factor: 7.853

4.  Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.

Authors:  Jennifer E Davoren; Michelle Garnsey; Betty Pettersen; Michael A Brodney; Jeremy R Edgerton; Jean-Philippe Fortin; Sarah Grimwood; Anthony R Harris; Stephen Jenkinson; Terry Kenakin; John T Lazzaro; Che-Wah Lee; Susan M Lotarski; Lisa Nottebaum; Steven V O'Neil; Michael Popiolek; Simeon Ramsey; Stefanus J Steyn; Catherine A Thorn; Lei Zhang; Damien Webb
Journal:  J Med Chem       Date:  2017-07-26       Impact factor: 7.446

5.  Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model.

Authors:  Evan P Lebois; Jason P Schroeder; Thomas J Esparza; Thomas M Bridges; Craig W Lindsley; P Jeffrey Conn; David L Brody; J Scott Daniels; Allan I Levey
Journal:  ACS Chem Neurosci       Date:  2017-03-07       Impact factor: 4.418

6.  M1 Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder.

Authors:  James Maksymetz; Max E Joffe; Sean P Moran; Branden J Stansley; Brianna Li; Kayla Temple; Darren W Engers; J Josh Lawrence; Craig W Lindsley; P Jeffrey Conn
Journal:  Biol Psychiatry       Date:  2019-03-07       Impact factor: 13.382

7.  A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

Authors:  Jana K Shirey; Ashley E Brady; Paulianda J Jones; Albert A Davis; Thomas M Bridges; J Phillip Kennedy; Satyawan B Jadhav; Usha N Menon; Zixiu Xiang; Mona L Watson; Edward P Christian; James J Doherty; Michael C Quirk; Dean H Snyder; James J Lah; Allan I Levey; Michelle M Nicolle; Craig W Lindsley; P Jeffrey Conn
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

Review 8.  Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.

Authors:  Samantha E Yohn; P Jeffrey Conn
Journal:  Neuropharmacology       Date:  2017-09-09       Impact factor: 5.250

9.  M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition.

Authors:  Sean P Moran; Jonathan W Dickerson; Hyekyung P Cho; Zixiu Xiang; James Maksymetz; Daniel H Remke; Xiaohui Lv; Catherine A Doyle; Deepa H Rajan; Colleen M Niswender; Darren W Engers; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2018-03-14       Impact factor: 7.853

10.  Design and optimization of selective azaindole amide M1 positive allosteric modulators.

Authors:  Jennifer E Davoren; Steven V O'Neil; Dennis P Anderson; Michael A Brodney; Lois Chenard; Keith Dlugolenski; Jeremy R Edgerton; Michael Green; Michelle Garnsey; Sarah Grimwood; Anthony R Harris; Gregory W Kauffman; Erik LaChapelle; John T Lazzaro; Che-Wah Lee; Susan M Lotarski; Deane M Nason; R Scott Obach; Veronica Reinhart; Romelia Salomon-Ferrer; Stefanus J Steyn; Damien Webb; Jiangli Yan; Lei Zhang
Journal:  Bioorg Med Chem Lett       Date:  2015-11-17       Impact factor: 2.823

View more
  5 in total

Review 1.  CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?

Authors:  Thamizhselvi Ganapathy; Rajalingam Radhakrishnan; Seth Sakshi; Sunil Martin
Journal:  Cancer Immunol Immunother       Date:  2022-08-12       Impact factor: 6.630

Review 2.  Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Louis Dwomoh; Gonzalo S Tejeda; Andrew B Tobin
Journal:  Neuronal Signal       Date:  2022-04-21

Review 3.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

Review 4.  Targeting muscarinic receptors to treat schizophrenia.

Authors:  Daniel J Foster; Zoey K Bryant; P Jeffrey Conn
Journal:  Behav Brain Res       Date:  2021-02-26       Impact factor: 3.332

Review 5.  Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias.

Authors:  Emma T van der Westhuizen; K H Christopher Choy; Celine Valant; Simon McKenzie-Nickson; Sophie J Bradley; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.